Sow, Papa Salif; Watson-Jones, Deborah; Kiviat, Nancy; Changalucha, John; Mbaye, Khardiata Diallo; Brown, Joelle; Bousso, Kouro; Kavishe, Bazil; Andreasen, Aura; Toure, Macoumba; +7 more... Kapiga, Saidi; Mayaud, Philippe; Hayes, Richard; Lebacq, Marie; Herazeh, Marjan; Thomas, Florence; Descamps, Dominique; (2013) Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women. The Journal of infectious diseases, 207 (11). pp. 1753-1763. ISSN 0022-1899 DOI: https://doi.org/10.1093/infdis/jis619
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Abstract
BACKGROUND: Cervical cancer is a major public health problem for women in sub-Saharan Africa. Availability of a human papillomavirus (HPV) vaccine could have an important public health impact. METHODS: In this phase IIIb, double-blind, randomized, placebo-controlled, multicenter trial (NCT00481767), healthy African girls and young women seronegative for human immunodeficiency virus (HIV) were stratified by age (10-14 or 15-25 years) and randomized (2:1) to receive either HPV-16/18 AS04-adjuvanted vaccine (n = 450) or placebo (n = 226) at 0, 1, and 6 months. The primary objective was to evaluate HPV-16/18 antibody responses at month 7. Seropositivity rates and corresponding geometric mean titers (GMTs) were measured by enzyme-linked immunosorbent assay. RESULTS: In the according-to-protocol analysis at month 7, 100% of initially seronegative participants in the vaccine group were seropositive for both anti-HPV-16 and anti-HPV-18 antibodies (n = 130 and n = 128 for 10-14-year-olds, respectively; n = 190 and n = 212 for 15-25-year-olds). GMTs for HPV-16 and HPV-18 were higher in 10-14-year-olds (18 423 [95% confidence interval, 16 185-20 970] and 6487 [5590-7529] enzyme-linked immunosorbent assay units (EU)/mL, respectively) than in 15-25-year-olds (10 683 [9567-11 930] and 3743 [3400-4120] EU/mL, respectively). Seropositivity was maintained at month 12. No participant withdrew owing to adverse events. No vaccine-related serious adverse events were reported. CONCLUSIONS: The HPV-16/18 AS04-adjuvanted vaccine was highly immunogenic and had a clinically acceptable safety profile when administered to healthy HIV-seronegative African girls and young women.
Item Type | Article |
---|---|
Faculty and Department |
Faculty of Infectious and Tropical Diseases > Dept of Clinical Research Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology & International Health (2023-) |
Research Centre |
Centre for Maternal, Reproductive and Child Health (MARCH) Vaccine Centre Tropical Epidemiology Group |
PubMed ID | 23242542 |
ISI | 318563200016 |
Related URLs |
Download
Filename: jis619.pdf
Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0
Download